Skip to content
Calculator
Evidence: HighPeptide conjugateFDA ApprovedPegylated cyclic peptideFDA-approved 2021 · Empaveli2023 · Syfovre (eye)

Pegcetacoplan

A complement C3 blocker for a blood disease, two kidney diseases and an eye disease

Pegcetacoplan joins two cyclic peptides to a PEG chain and blocks complement protein C3. As Empaveli it treats PNH and two kidney diseases; as Syfovre, injected into the eye, it slows geographic atrophy.

Manufacturer's recommended dosing (FDA label): 1,080 mg, Twice weekly, Subcutaneous infusion Details ↓

Overview

What is it?

Complement is a cascade of blood proteins that tags and destroys microbes, and several diseases come from it attacking the body's own tissue. Older complement drugs such as eculizumab block C5 near the end of the cascade; pegcetacoplan blocks C3 at its centre, which also stops the clearance of coated red cells outside blood vessels.

In paroxysmal nocturnal haemoglobinuria (PNH), red cells lack protection from complement and are destroyed. In PEGASUS, patients still anaemic on eculizumab who switched to pegcetacoplan gained 3.84 g/dL more haemoglobin by week 16. Approved as Empaveli in 2021, it was later approved for C3 glomerulopathy and immune-complex MPGN after the VALIANT trial cut urine protein by 68% relative to placebo.

As Syfovre it is injected into the eye. In OAKS and DERBY it slowed the growth of geographic atrophy, the advanced dry form of macular degeneration, by up to 22% at two years, without improving vision tests. Empaveli carries a boxed warning for serious infections from encapsulated bacteria; Syfovre's label warns of endophthalmitis, retinal vasculitis and intraocular inflammation.

The PNH results have held up over time. Across PEGASUS, the PRINCE trial in patients who had never taken a complement inhibitor, and their extension, haemoglobin and fatigue stayed near normal for up to three years, with 71% to 86% of patients avoiding transfusion each year. Breakthrough haemolysis, a flare when complement activity rises during infection or a missed dose, is the main limitation, and a 2026 indirect comparison written with staff of Sobi, the company behind it in Europe, against the newer C5 inhibitor crovalimab favoured pegcetacoplan, though indirect comparisons cannot replace a head-to-head trial.

In the eye the picture is more mixed. Slowing the growth of geographic atrophy has not translated into better vision in the two-year trials, and the open-label GALE extension, which reported larger reductions over three years, compared patients with a projection rather than a randomised sham group. In Europe the two uses split: the PNH form is authorised as Aspaveli, while the European Medicines Agency refused authorisation for Syfovre, so the eye injection is available in the US but not the EU (EMA medicines dataset, read October 5, 2026).

The 2026 evidence adds detail on each use. In adolescents with C3 glomerulopathy or immune-complex MPGN in VALIANT, proteinuria fell by three quarters against placebo, a larger share met the kidney endpoint, and no one had the encapsulated-bacteria infections that complement blockade can invite. Pooled PNH studies of 271 patients put transfusion avoidance at about 80%, with breakthrough haemolysis in about one in seven. In the eye, the subfoveal subgroup of the geographic atrophy trials, where vision is most at stake, showed slower lesion growth over three years, but a case of occlusive retinal vasculitis ending in loss of light perception after a single injection is a reminder of the rare inflammatory risk that has shaped how it is used.

+3.84 g/dL
haemoglobin vs eculizumab at week 16
PEGASUS, 80 adults with PNH (2021) · PMID 33730455
−67.2% vs +2.9%
urine protein at 26 weeks
VALIANT, C3G and IC-MPGN (2025) · PMID 41337715
16–22%
slower geographic atrophy growth
OAKS and DERBY, 24 months, vision unchanged · PMID 37865470
Boxed warning
serious infections
Empaveli label
Science

Mechanism of Action

Pegcetacoplan blocks complement at its hub, the C3 protein, rather than at the end of the cascade like older drugs.

🧩

C3 inhibition

It binds C3 and its fragment C3b, stopping the step that amplifies the whole complement cascade, so neither the membrane attack complex nor C3 coating on cells forms.

🩸

Both kinds of haemolysis in PNH

C5 blockers stop red cells bursting in the bloodstream but leave them coated with C3 and cleared in the liver and spleen; blocking C3 addresses both, which is why PEGASUS patients still anaemic on eculizumab improved.

🧪

PEGylated cyclic peptide

Two copies of a compstatin-family cyclic peptide are joined to polyethylene glycol, which slows clearance enough for twice-weekly infusion under the skin.

👁

Local action in the eye

Injected into the eye as Syfovre, it acts on complement activity in the retina thought to drive geographic atrophy, without exposing the whole body.

Evidence

Published Research

The studies behind pegcetacoplan, read from their PubMed abstracts, with dosing from both labels read October 3, 2026.

Human2021

PEGASUS: against eculizumab in PNH

In 80 adults still anaemic on eculizumab, pegcetacoplan raised haemoglobin by 3.84 g/dL more by week 16, and 85% against 15% no longer needed transfusions. Injection-site reactions (37% against 3%) were more common, breakthrough haemolysis less common.

PMID: 33730455
Human2025

Three years in PNH

Across PEGASUS, PRINCE and their extension, haemoglobin and fatigue stayed near normal for up to three years, with yearly transfusion avoidance of 71% to 86%; breakthrough haemolysis occurred in 28%.

PMID: 40720060
Human2024

PNH with milder anaemia

In 25 patients whose haemoglobin was already 10 g/dL or more, 16 weeks raised it to about 12.7 to 14.0 g/dL.

PMID: 39079163
Human2025

VALIANT: C3G and IC-MPGN

In 124 adolescents and adults, urine protein fell 67.2% on pegcetacoplan against a 2.9% rise on placebo at 26 weeks; 49% against 3% met a composite kidney end point. A biopsy activity score did not differ significantly.

PMID: 41337715
Human2023

OAKS and DERBY: geographic atrophy

In 1,258 patients, injections slowed lesion growth at 24 months by 16% to 22% against sham; DERBY missed its 12-month end point. Vision did not differ, and new wet macular degeneration occurred in 6% to 13% of treated patients against 2% to 4% on sham.

PMID: 37865470
Human2025

GALE: 36 months in the eye

In an open-label extension retaining 92% of 790 patients, lesion growth was reduced by up to 32% against projected sham, more each year.

PMID: 40280279
Human2026

Adolescents in VALIANT

Among 55 adolescents with C3 glomerulopathy or primary immune-complex MPGN, pegcetacoplan cut proteinuria by 75% relative to placebo, and 57% against 4% met the composite kidney endpoint. Three in each arm had serious adverse events; none had an infection with encapsulated bacteria.

PMID: 42133432
Human2026

Subfoveal geographic atrophy over three years

In the subfoveal subgroup of OAKS, DERBY and GALE, where 84% still had mild or moderate visual impairment, monthly or every-other-month injections slowed lesion growth over three years and may have lowered the risk of new blind spots.

PMID: 42164977
Human2026

Retinal vasculitis after a first injection

A case report: 10 days after a single intravitreal injection, a patient developed raised eye pressure and presumed occlusive retinal vasculitis, and vision fell from 20/50 to no light perception, with cultures negative. It remains a rare but severe event.

PMID: 42577845
Review2026

Indirect comparison with crovalimab

Using patient-level data from PRINCE and PEGASUS against published crovalimab trials, matching-adjusted and Bucher indirect comparisons favoured pegcetacoplan on transfusion avoidance, haemoglobin and haemolysis control; indirect comparisons carry more uncertainty than direct trials.

PMID: 42636034
Review2026

PNH, pooled

Across five studies of 271 patients with PNH, 80.6% avoided transfusion, LDH normalised in 68.5% and haemoglobin in 42.9%. Serious adverse events occurred in 16.6%, breakthrough haemolysis in 14.8% and infections in 17%.

PMID: 42322093
Review2026

Against iptacopan in C3G, indirectly

Indirect comparisons of the VALIANT and APPEAR-C3G placebo-controlled trials found greater proteinuria reduction with pegcetacoplan than with iptacopan at 6 and 12 months, with no difference in eGFR. Indirect comparisons cannot replace a head-to-head trial.

PMID: 42138781
Dosing

Dosing Data

Pegcetacoplan has two labels. As Empaveli it is infused under the skin at 1,080 mg twice weekly for PNH and for C3 glomerulopathy or IC-MPGN in adults; as Syfovre it is injected into the eye at 15 mg every 25 to 60 days.

Not a recommendation. Empaveli requires vaccination against encapsulated bacteria and a restricted distribution programme because of its boxed warning for serious infections; Syfovre is given only by an eye specialist.
ProtocolDoseFrequencyDurationRoute
Empaveli: PNH, C3G and IC-MPGN (adults) Approved labelEmpaveli prescribing information, section 2 (DailyMed set c23d89e9, version 14, effective August 21, 2026)1,080 mgTwice weeklyOngoingSubcutaneous infusion
Syfovre: geographic atrophy Approved labelSyfovre prescribing information, section 2 (DailyMed set b4434e61, version 12, effective September 16, 2025)15 mg (0.1 mL) per eyeEvery 25 to 60 daysOngoingIntravitreal

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Supplied ready to use
Empaveli comes in vials for a small infusion pump and Syfovre is a single-use intravitreal dose; there is nothing to reconstitute.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved products, as their labels describe them:

  • Empaveli (pegcetacoplan injection): Injection: 1,080 mg/20 mL (54 mg/mL) in a single-dose vial. Forms the label lists: single-dose vials.
  • Syfovre (pegcetacoplan injection): Injection: 150 mg/mL in a single-dose vial. Forms the label lists: single-dose vials.

Source: Empaveli (pegcetacoplan injection) label, section 3 (DailyMed version 14, effective August 21, 2026); Syfovre (pegcetacoplan injection) label, section 3 (DailyMed version 12, effective September 16, 2025).

Mixing a vial: a worked example

Nothing to mix: the label gives Empaveli (pegcetacoplan injection) as single-dose vials, ready to use.

Source: Empaveli (pegcetacoplan injection) label, sections 2, 3 and 16 (DailyMed version 14, effective August 21, 2026).

Storage before and after mixing

Before mixing or first use: “Store vials of EMPAVELI refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.” “Refrigerate SYFOVRE between 2°C to 8°C (36°F to 46°F).” “Store the vial in the original carton to protect from light.”

After mixing or first use: “Discard any unused portion of EMPAVELI.”

Source: Empaveli (pegcetacoplan injection) label, sections 16 and 2 (DailyMed version 14, effective August 21, 2026); Syfovre (pegcetacoplan injection) label, sections 16 and 2 (DailyMed version 12, effective September 16, 2025).

How it is taken

As the approved label gives it: Subcutaneous infusion (Twice weekly; Empaveli: PNH, C3G and IC-MPGN (adults)); Intravitreal (Every 25 to 60 days; Syfovre: geographic atrophy).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of 8.6 days (subcutaneous, PNH); 10.2 days (C3G/IC-MPGN); 4.5 days (intravitreal, geographic atrophy). After about five half-lives almost none is left.

When effects appear: unknown; no source on this page gives a time to effect for Pegcetacoplan. Results reported in the studies are under Published Research.

Source: half-life: Empaveli prescribing information, section 12.3 (DailyMed set c23d89e9, version 14, effective August 21, 2026); Syfovre prescribing information, section 12.3 (DailyMed set b4434e61, version 12, effective September 16, 2025).

Side effects, and when to stop or get help

From the Side Effects section: Injection-site reactions and diarrhoea (Empaveli); Breakthrough haemolysis in PNH; New wet macular degeneration (Syfovre). Full list and cautions ↓

Boxed warning on the label: Serious infections caused by encapsulated bacteria.

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Pegcetacoplan. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: Empaveli (pegcetacoplan injection) label, boxed warning and section 5 (DailyMed version 14, effective August 21, 2026); the Side Effects section below (“From the studies above”).

Interactions

Unknown: a PubMed search for human interaction studies of Pegcetacoplan (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Pegcetacoplan products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Pegcetacoplan's expected mass, 43,500.0 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (Approved in the US as Empaveli (pegcetacoplan), NDA 215014, on May 14, 2021, for PNH, with a later indication for C3 glomerulopathy and primary IC-MPGN). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Injection-site reactions and diarrhoea (Empaveli)
● Breakthrough haemolysis in PNH
● New wet macular degeneration (Syfovre)

Contraindications & Cautions

Warnings from the Empaveli (DailyMed, effective August 21, 2026) and Syfovre (effective September 16, 2025) labels.

● Boxed warning: serious infections caused by encapsulated bacteria; vaccination required, and Empaveli is available only through a REMS
● Monitoring for PNH manifestations after stopping Empaveli
● Interference with some laboratory tests
● Syfovre: endophthalmitis, retinal detachment, retinal vasculitis or vascular occlusion, wet macular degeneration, intraocular inflammation and raised eye pressure
Questions

Frequently Asked Questions

?What is pegcetacoplan?

Two cyclic peptides joined by a polyethylene glycol chain that block complement protein C3, sold as Empaveli for PNH and two kidney diseases and as Syfovre for geographic atrophy.

?How is it different from eculizumab?

Eculizumab blocks C5, late in the complement cascade; pegcetacoplan blocks C3, earlier, which also stops red cell destruction outside vessels.

?Does Syfovre improve vision?

No. In OAKS and DERBY it slowed lesion growth but did not improve vision tests over two years.

?Why do I need vaccines before Empaveli?

Blocking complement weakens defence against encapsulated bacteria such as meningococcus and pneumococcus; the label requires vaccination and carries a boxed warning for serious infections.

?Does Syfovre improve vision?

No. In OAKS and DERBY it slowed the growth of geographic atrophy but vision tests did not differ from sham over two years.

?Is pegcetacoplan available in Europe?

For PNH, yes, under the name Aspaveli. The eye product, Syfovre, was refused authorisation by the European Medicines Agency.

?How is pegcetacoplan different from eculizumab?

Eculizumab blocks C5 near the end of the complement cascade, stopping red cells bursting in the blood; pegcetacoplan blocks C3 earlier, which also stops coated red cells being removed in the liver and spleen. In PEGASUS, patients still anaemic on eculizumab gained 3.84 g/dL more haemoglobin after switching.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): EMPAVELI (pegcetacoplan), NDA 215014, original approval May 14, 2021; SYFOVRE (pegcetacoplan), NDA 217171, original approval February 17, 2023; both prescription. Read October 3, 2026.
  2. [fda-pi] FDA. Empaveli (pegcetacoplan) US prescribing information (DailyMed set c23d89e9-b00b-4520-e053-2995a90a95af, version 14, effective August 21, 2026). Read October 3, 2026.
  3. [fda-pi] FDA. Syfovre (pegcetacoplan) US prescribing information (DailyMed set b4434e61-9ec9-4e0e-bd60-45aaa0a87e64, version 12, effective September 16, 2025). Read October 3, 2026.
  4. [pubmed] Hillmen P, et al. "Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria." N Engl J Med, 2021;384(11):1028-1037. PMID: 33730455.
  5. [pubmed] de Castro C, et al. "Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan." Adv Ther, 2025;42(9):4641-4658. PMID: 40720060.
  6. [pubmed] Panse J, et al. "Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors." PLoS One, 2024;19(7):e0306407. PMID: 39079163.
  7. [pubmed] Fakhouri F, et al. "Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN." N Engl J Med, 2025;393(22):2210-2220. PMID: 41337715.
  8. [pubmed] Heier JS, et al. "Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials." Lancet, 2023;402(10411):1434-1448. PMID: 37865470.
  9. [pubmed] Wykoff CC, et al. "Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE." Am J Ophthalmol, 2025;276:350-364. PMID: 40280279.
  10. [pubmed] Ming Wong RS, et al. "Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria." J Comp Eff Res, 2026;15(10):e260015. PMID: 42636034.
  11. [other] EMA medicines dataset: Aspaveli (pegcetacoplan), authorised; Syfovre (pegcetacoplan), refused. Read October 5, 2026.
  12. [pubmed] Vivarelli M, et al. "Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis." Clin J Am Soc Nephrol, 2026;21(8):1404-1413. PMID: 42133432.
  13. [pubmed] Martins KAM, et al. "Efficacy and Safety of the C3 Inhibitor Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis." Eur J Haematol, 2026;117(4):838-848. PMID: 42322093.
  14. [pubmed] Dixon BP, et al. "Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons." Adv Ther, 2026;43(8):3385-3402. PMID: 42138781.
  15. [pubmed] Dhoot DS, et al. "Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension." Clin Ophthalmol, 2026;20:579237. PMID: 42164977.
  16. [pubmed] Seela JR, et al. "Intraocular inflammation and presumed retinal vasculitis following initial pegcetacoplan intravitreal injection." Digit J Ophthalmol, 2026;32(2):50-53. PMID: 42577845.

Sources & Citations

Studies were read from their PubMed records; regulatory sources are listed below, read October 3, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-05